

Catherine Sautes-fridman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8011926/catherine-sautes-fridman-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167
papers

19,142
citations

70
h-index

137
g-index

192
ext. papers

25,034
ext. citations

8.9
avg, IF

6.83
L-index

#	Paper	IF	Citations
167	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , 2012 , 12, 298-306	31.3	2819
166	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 717-734	19.4	935
165	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. <i>Genome Biology</i> , 2016 , 17, 218	18.3	791
164	Immune infiltration in human tumors: a prognostic factor that should not be ignored. <i>Oncogene</i> , 2010 , 29, 1093-102	9.2	725
163	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020 , 577, 549-555	50.4	654
162	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020 , 577, 556-560	50.4	538
161	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019 , 49, 1457-1973	6.1	485
160	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019 , 19, 307-325	32.5	397
159	Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 832-44	10.2	340
158	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 4057-66	12.9	306
157	Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. <i>Cancer Research</i> , 2014 , 74, 705-15	10.1	306
156	Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. <i>Cancer Research</i> , 2011 , 71, 5412-22	10.1	302
155	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
154	Prognostic and predictive impact of intra- and peritumoral immune infiltrates. <i>Cancer Research</i> , 2011 , 71, 5601-5	10.1	297
153	Tertiary lymphoid structures in cancer and beyond. <i>Trends in Immunology</i> , 2014 , 35, 571-80	14.4	288
152	The structure of a human type III Fcγ receptor in complex with Fc. <i>Journal of Biological Chemistry</i> , 2001 , 276, 16469-77	5.4	286
151	A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. <i>Blood</i> , 2006 , 107, 190-6	2.2	280

150	Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. <i>Blood</i> , 2002 , 99, 2114-21	2.2	266
149	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3031-40	12.9	249
148	Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. <i>Cancer Research</i> , 1999 , 59, 3698-704	10.1	215
147	Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. <i>Clinical Cancer Research</i> , 2013 , 19, 4079-91	12.9	213
146	Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. <i>Journal of Immunology</i> , 2001 , 166, 531-7	5.3	200
145	Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. <i>Cancer Research</i> , 2011 , 71, 6391-9	10.1	196
144	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 4416-4428	12.9	174
143	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. <i>OncolImmunology</i> , 2012 , 1, 1323-1343	7.2	173
142	Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. <i>Clinical Cancer Research</i> , 2015 , 21, 1329-39	12.9	172
141	CD14 ^{dim} CD16 ⁺ and CD14 ⁺ CD16 ⁺ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 2322-30	9.4	170
140	Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. <i>Immunological Reviews</i> , 2016 , 271, 260-75	11.3	167
139	Trial watch: IDO inhibitors in cancer therapy. <i>OncolImmunology</i> , 2014 , 3, e957994	7.2	166
138	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. <i>OncolImmunology</i> , 2012 , 1, 699-716	7.2	164
137	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>OncolImmunology</i> , 2012 , 1, 894-907	7.2	163
136	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>OncolImmunology</i> , 2015 , 4, e1008866	7.2	162
135	The clinical role of the TME in solid cancer. <i>British Journal of Cancer</i> , 2019 , 120, 45-53	8.7	155
134	Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. <i>Frontiers in Immunology</i> , 2016 , 7, 407	8.4	154
133	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1285-97	15.9	153

132	The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 377-90	10.2	140
131	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>OncolImmunology</i> , 2012 , 1, 1111-1134	7.2	134
130	The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. <i>Journal of Medical Genetics</i> , 2009 , 46, 447-50	5.8	132
129	Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. <i>Kidney International</i> , 2010 , 77, 339-49	9.9	131
128	Immune infiltration in human cancer: prognostic significance and disease control. <i>Current Topics in Microbiology and Immunology</i> , 2011 , 344, 1-24	3.3	126
127	Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. <i>Cancer Research</i> , 2016 , 76, 1746-56	10.1	122
126	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016 , 130, 95-190	5.6	120
125	Trial Watch: Toll-like receptor agonists for cancer therapy. <i>OncolImmunology</i> , 2013 , 2, e25238	7.2	120
124	Alternative complement pathway assessment in patients with atypical HUS. <i>Journal of Immunological Methods</i> , 2011 , 365, 8-26	2.5	119
123	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. <i>Blood</i> , 2009 , 114, 2837-45	2.2	119
122	Trial Watch: Chemotherapy with immunogenic cell death inducers. <i>OncolImmunology</i> , 2014 , 3, e27878	7.2	116
121	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. <i>Blood</i> , 2012 , 119, 4182-91	2.2	107
120	Prognostic impact of vitamin B6 metabolism in lung cancer. <i>Cell Reports</i> , 2012 , 2, 257-69	10.6	100
119	Context-dependent roles of complement in cancer. <i>Nature Reviews Cancer</i> , 2019 , 19, 698-715	31.3	99
118	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020 , 11, 784	8.4	98
117	Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling. <i>Cell Metabolism</i> , 2015 , 22, 113-24	24.6	96
116	Trial watch: Oncolytic viruses for cancer therapy. <i>OncolImmunology</i> , 2013 , 2, e24612	7.2	94
115	Cancer immune contexture and immunotherapy. <i>Current Opinion in Immunology</i> , 2016 , 39, 7-13	7.8	93

114	The immune microenvironment of human tumors: general significance and clinical impact. <i>Cancer Microenvironment</i> , 2013 , 6, 117-22	6.1	93
113	Characteristics of tertiary lymphoid structures in primary cancers. <i>OncolImmunology</i> , 2013 , 2, e26836	7.2	86
112	Tumor microenvironment is multifaceted. <i>Cancer and Metastasis Reviews</i> , 2011 , 30, 13-25	9.6	86
111	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>OncolImmunology</i> , 2012 , 1, 179-188	7.2	86
110	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019 , 70, 58-65	13.4	86
109	The immune contexture of primary and metastatic human tumours. <i>Current Opinion in Immunology</i> , 2014 , 27, 8-15	7.8	85
108	Trial Watch: Peptide vaccines in cancer therapy. <i>OncolImmunology</i> , 2013 , 2, e26621	7.2	84
107	Trial Watch: Peptide-based anticancer vaccines. <i>OncolImmunology</i> , 2015 , 4, e974411	7.2	81
106	Trial Watch: Monoclonal antibodies in cancer therapy. <i>OncolImmunology</i> , 2012 , 1, 28-37	7.2	80
105	Crystal structure of the extracellular domain of a human Fc gamma RIII. <i>Immunity</i> , 2000 , 13, 387-95	32.3	80
104	Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. <i>Journal of Immunology</i> , 2012 , 189, 3528-37	5.3	78
103	Fc gamma receptors. <i>Immunology Letters</i> , 2004 , 92, 199-205	4.1	78
102	Trial Watch-Oncolytic viruses and cancer therapy. <i>OncolImmunology</i> , 2016 , 5, e1117740	7.2	76
101	Trial watch: Monoclonal antibodies in cancer therapy. <i>OncolImmunology</i> , 2013 , 2, e22789	7.2	76
100	Trial Watch: Anticancer radioimmunotherapy. <i>OncolImmunology</i> , 2013 , 2, e25595	7.2	75
99	Trial watch: Peptide vaccines in cancer therapy. <i>OncolImmunology</i> , 2012 , 1, 1557-1576	7.2	73
98	Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. <i>Blood</i> , 2002 , 100, 3646-55	2.2	72
97	The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. <i>Chest</i> , 2014 , 146, 633-643	5.3	70

96	Structural basis of the interaction between IgG and Fcγ receptors. <i>Journal of Molecular Biology</i> , 2000 , 295, 213-24	6.5	70
95	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. <i>Cancer Immunology Research</i> , 2019 , 7, 1091-1105	12.5	68
94	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients 2018 , 6, 139		66
93	Profiling of the three circulating monocyte subpopulations in human obesity. <i>Journal of Immunology</i> , 2015 , 194, 3917-23	5.3	64
92	TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. <i>Cancer Research</i> , 2014 , 74, 5008-18	10.1	64
91	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. <i>Oncotarget</i> , 2014 , 3, e27048	7.2	64
90	Trial Watch: Toll-like receptor agonists in oncological indications. <i>Oncotarget</i> , 2014 , 3, e29179	7.2	61
89	TRAF4 overexpression is a common characteristic of human carcinomas. <i>Oncogene</i> , 2007 , 26, 142-7	9.2	61
88	PD-L1 Expression and CD8 T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 192-196	5.1	60
87	Measles virus nucleoprotein induces cell-proliferation arrest and apoptosis through NTAI-NR and NCORE-FcγRIIB1 interactions, respectively. <i>Journal of General Virology</i> , 2005 , 86, 1771-1784	4.9	59
86	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 981-988	7.4	58
85	Trial Watch: Adoptive cell transfer immunotherapy. <i>Oncotarget</i> , 2012 , 1, 306-315	7.2	58
84	Association of FcγRII with low-density detergent-resistant membranes is important for cross-linking-dependent initiation of the tyrosine phosphorylation pathway and superoxide generation. <i>Journal of Immunology</i> , 2001 , 167, 5814-23	5.3	56
83	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. <i>Journal of Autoimmunity</i> , 2011 , 36, 9-15	15.5	55
82	Murine models of B-cell lymphomas: promising tools for designing cancer therapies. <i>Advances in Hematology</i> , 2012 , 2012, 701704	1.5	50
81	The immune microenvironment: a major player in human cancers. <i>International Archives of Allergy and Immunology</i> , 2014 , 164, 13-26	3.7	49
80	Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. <i>Frontiers in Immunology</i> , 2013 , 4, 19	8.4	48
79	Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. <i>PLoS ONE</i> , 2013 , 8, e52385	3.7	43

78	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015 , 467, 127-35	5.1	42
77	Association of IL-36 with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 109-120	7.4	37
76	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>OncImmunity</i> , 2015 , 4, e1049804	7.2	34
75	Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. <i>Immunology Letters</i> , 1999 , 68, 125-34	4.1	34
74	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 7351-7362	12.9	33
73	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2018 , 8, 390	5.3	31
72	Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. <i>Journal of Immunology</i> , 2001 , 166, 3377-83	5.3	30
71	Mannose receptor ligand-positive cells express the metalloprotease decysin in the B cell follicle. <i>Journal of Immunology</i> , 2001 , 167, 5052-60	5.3	29
70	Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas 2013 , 54, 3657-65		27
69	Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2008 , 30, 238-45	15.5	27
68	Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. <i>Investigative Ophthalmology and Visual Science</i> , 2007 , 48, 3223-9		27
67	Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. <i>International Journal of Cancer</i> , 2008 , 123, 2832-9	7.5	26
66	Modulation of tumor growth by inhibitory Fc receptor expressed by human melanoma cells. <i>Journal of Clinical Investigation</i> , 2002 , 110, 1549-1557	15.9	26
65	Shaping of an effective immune microenvironment to and by cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 991-7	7.4	25
64	B cells and cancer: To B or not to B?. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	25
63	Tumor microenvironment in NSCLC suppresses NK cells function. <i>OncImmunity</i> , 2012 , 1, 244-246	7.2	24
62	FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer. <i>British Journal of Cancer</i> , 2012 , 106, 1989-96	8.7	24
61	Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited. <i>European Journal of Immunology</i> , 2007 , 37, 1377-85	6.1	24

60	FcγRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. <i>British Journal of Haematology</i> , 2004 , 124, 55-62	4.5	23
59	Control of tumor development by intratumoral cytokines. <i>Immunology Letters</i> , 1999 , 68, 135-9	4.1	23
58	Therapeutic Targeting of the Colorectal Tumor Stroma. <i>Gastroenterology</i> , 2020 , 158, 303-321	13.3	23
57	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer 2020 , 8,		23
56	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e981-e994	3.3	22
55	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Onc Immunology</i> , 2015 , 4, e1026531	7.2	22
54	Characterization of immune functions in TRAF4-deficient mice. <i>Immunology</i> , 2008 , 124, 562-74	7.8	22
53	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. <i>Clinical Cancer Research</i> , 2020 , 26, 4381-4389	12.9	21
52	Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma. <i>PLoS ONE</i> , 2011 , 6, e24622	3.7	21
51	LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. <i>Annals of Oncology</i> , 2020 , 31, S1157	10.3	19
50	Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. <i>Onc Immunology</i> , 2014 , 3, e28976	7.2	19
49	N-glycosylation profile of recombinant human soluble Fcγ receptor III. <i>Glycobiology</i> , 2002 , 12, 507-518	3.8	19
48	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.. <i>Nature Cancer</i> , 2021 , 2, 794-802	15.4	19
47	Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum. <i>Scientific Reports</i> , 2018 , 8, 2719	4.9	18
46	TLS in Tumors: What Lies Within. <i>Trends in Immunology</i> , 2016 , 37, 1-2	14.4	18
45	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. <i>Genome Medicine</i> , 2020 , 12, 86	14.4	17
44	Dendritic cells in the tumor microenvironment: prognostic and theranostic impact. <i>Seminars in Immunology</i> , 2020 , 48, 101410	10.7	15
43	Revisiting immune escape in colorectal cancer in the era of immunotherapy. <i>British Journal of Cancer</i> , 2019 , 120, 815-818	8.7	13

42	Complement System: Promoter or Suppressor of Cancer Progression?. <i>Antibodies</i> , 2020 , 9,	7	13
41	Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	13
40	Metastatic melanomas express inhibitory low affinity Fc gamma receptor and escape humoral immunity. <i>Dermatology Research and Practice</i> , 2010 , 2010, 657406	2	13
39	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. <i>Seminars in Immunology</i> , 2020 , 48, 101406	10.7	13
38	Immune-based identification of cancer patients at high risk of progression. <i>Current Opinion in Immunology</i> , 2018 , 51, 97-102	7.8	12
37	Activation of human peripheral IgM+ B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB. <i>Journal of Immunology</i> , 2008 , 181, 5350-9	5.3	12
36	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 463-474	5.1	12
35	Fc gamma receptors and cancer. <i>Seminars in Immunopathology</i> , 2006 , 28, 321-8		11
34	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.. <i>Immunity</i> , 2022 ,	32.3	11
33	FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). <i>Leukemia</i> , 2004 , 18, 2038-40	10.7	10
32	Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line. <i>Immunology Letters</i> , 2000 , 75, 1-8	4.1	10
31	Presentation of antigen in immune complexes is boosted by soluble bacterial immunoglobulin binding proteins. <i>Journal of Experimental Medicine</i> , 1999 , 189, 1217-28	16.6	10
30	Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells. <i>Journal of Clinical Investigation</i> , 2002 , 110, 1549-57	15.9	10
29	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2021 ,	12.9	10
28	Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013 , 32, 18	12.8	9
27	Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics. <i>Clinical and Experimental Immunology</i> , 2011 , 165, 329-37	6.2	9
26	Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. <i>Frontiers in Immunology</i> , 2012 , 3, 98	8.4	9
25	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011 , 2, 66	8.4	7

24	Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. <i>Cancer Immunology Research</i> , 2021 , 9, 909-925	12.5	7
23	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. <i>Cancer Immunology Research</i> , 2021 , 9, 891-908	12.5	7
22	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.. <i>Nature Reviews Clinical Oncology</i> , 2022 ,	19.4	7
21	Animal models of intraocular lymphomas. <i>Ophthalmic Research</i> , 2008 , 40, 208-11	2.9	6
20	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 643065	5.3	6
19	Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	6
18	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> ,	50.5	5
17	Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 9-18	4.8	4
16	7000 Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N). <i>Annals of Oncology</i> , 2020 , 31, S553	10.3	4
15	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11507-11507	2.2	4
14	Inhibition of human immunodeficiency virus transmission to CD4+ T cells after gene transfer of constitutively expressed interferon beta to dendritic cells. <i>Human Gene Therapy</i> , 2000 , 11, 1695-703	4.8	3
13	B cells and complement at the forefront of chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 393-394	19.4	2
12	NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N). <i>Annals of Oncology</i> , 2019 , 30, v360-v361	10.3	2
11	The immune microenvironments of lung and intraocular tumors. <i>Bulletin Du Cancer</i> , 2011 , 98, 58-61	2.4	2
10	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. <i>Methods in Molecular Biology</i> , 2021 , 2227, 191-203	1.4	2
9	C1q+ macrophages: passengers or drivers of cancer progression.. <i>Trends in Cancer</i> , 2022 ,	12.5	2
8	Tumor Immunology, toward a Success Story?. <i>Frontiers in Immunology</i> , 2015 , 6, 65	8.4	1
7	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. <i>Methods in Enzymology</i> , 2020 , 632, 15-25	1.7	1

6	The Human Tumor Microenvironment 2018 , 5-21		1
5	Primary Central Nervous System Lymphomas (PCNSL) Are Distinct from Systemic DLBCL for Expression Pattern of Germinal Center and Activation B-Cell Markers. A GOELAMS Study.. <i>Blood</i> , 2004 , 104, 2264-2264	2.2	1
4	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression		1
3	webMCP-counter: a web interface for transcriptomics-based quantification of immune and stromal cells in heterogeneous human or murine samples		1
2	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study 2022 , 10, e004885		0
1	The European Academy of Tumor Immunology: Bridging fields, continents and generations. <i>OncImmunology</i> , 2012 , 1, 127-128	7.2	